Can-Fite BioPharma Raises $5 Million in Public Offering

Can-Fite BioPharma ( (CANF) ) has provided an announcement.

On July 28, 2025, Can-Fite BioPharma Ltd. conducted a public offering, raising approximately $5.0 million through the sale of American Depositary Shares (ADSs) and warrants. The net proceeds of $4.19 million, after deducting fees and expenses, will be used for working capital, research and development, and clinical trials. This offering, expected to close on July 29, 2025, is part of the company’s strategy to strengthen its financial position and support its ongoing drug development efforts.

The most recent analyst rating on (CANF) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.

Spark’s Take on CANF Stock

According to Spark, TipRanks’ AI Analyst, CANF is a Underperform.

The overall stock score reflects significant financial challenges and bearish technical indicators. The company’s persistent financial losses and reliance on external financing are major concerns, compounded by negative technical signals. The absence of profitability metrics further underscores the risks associated with this stock.

To see Spark’s full report on CANF stock, click here.

More about Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a pharmaceutical company based in Israel, specializing in the development of small molecule drugs for the treatment of autoimmune inflammatory diseases, cancer, and liver conditions. The company focuses on advancing its proprietary drug candidates through clinical trials to address unmet medical needs in these areas.

Average Trading Volume: 164,574

Technical Sentiment Signal: Sell

Current Market Cap: $13.11M

For detailed information about CANF stock, go to TipRanks’ Stock Analysis page.